India’s health-tech scene just got its latest funding boost. Dectrocel, a cutting-edge AI-powered diagnostic startup, has raised Rs 4 crore in a fresh funding round led by IAN Group-powered BioAngels, with support from PadUp Ventures and Vinners.
Big names like Nitin Zamre, Samir Kalia, and Mitesh Shah participated in the round — signaling strong investor confidence in Dectrocel’s global ambitions.
What Dectrocel Does — And Why It Matters
Founded in 2020 by Ankit Shukla, Saumya Shukla, and Nikhil Mishra, Dectrocel is on a mission to reinvent healthcare diagnostics.
Its flagship product, DecXpert, has already made waves in the medical community. Approved by the Central Drugs Standard Control Organization (CDSCO), DecXpert is among only three AI-based diagnostic tools in India cleared for clinical use.
What makes it stand out?
- 10x faster interpretations of chest X-rays and CT scans
- 98% accuracy in detecting respiratory and hepato-pancreatico-biliary (HPB) diseases
- Trusted by clinicians for high-stakes decision-making
Where the Money’s Going
Dectrocel plans to use the fresh capital to:
- Scale commercial operations across India
- Expand into international markets
- Enhance its self-learning multimodal AI tech
- Accelerate rollout of new AI tools in CT, MRI, PET-CT, and HPB diagnostic modules
This roadmap could position Dectrocel as a global competitor in AI-driven diagnostics.
The Bigger Picture: Why Investors Are Excited
Healthcare AI is exploding worldwide, but adoption in clinical settings has been slow in India. That’s why investors see Dectrocel as a rare player with both regulatory approval and clinical validation.
With India’s healthcare market projected to hit $372 billion by 2025, Dectrocel’s AI-led solutions have the potential to cut costs, improve accuracy, and save lives at scale.
“We’re not just building AI tools; we’re building the future of diagnostics,” said Ankit Shukla, co-founder of Dectrocel.
What’s Next?
The startup is betting big on expanding beyond India, tapping into global healthcare systems hungry for cost-effective diagnostic solutions. If successful, Dectrocel could become a flag-bearer for Indian medtech innovation on the world stage.
